Schmitt C A, Rosenthal C T, Lowe S W
Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA.
Nat Med. 2000 Sep;6(9):1029-35. doi: 10.1038/79542.
Understanding the basis of chemoresistance is a principal goal of molecular oncology. We have exploited a murine lymphoma model and retroviral gene transfer to rapidly generate a series of spontaneous tumors differing only in a gene of interest, and subsequently studied the impact of the test gene on the treatment sensitivity of tumors at their natural site. We demonstrate that the Bcl-2 oncoprotein produces multi-drug resistance when assessed in primary lymphomas in vivo. In contrast, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and completely missed in the standard clonogenic survival assay. This model highlights the importance of physiological test systems to address the complexity of clinical drug resistance and provides a novel strategy to evaluate compounds targeting specific genetic lesions.
了解化疗耐药的基础是分子肿瘤学的主要目标。我们利用小鼠淋巴瘤模型和逆转录病毒基因转移技术,快速生成了一系列仅在感兴趣基因上存在差异的自发性肿瘤,随后研究了测试基因对肿瘤在其自然部位治疗敏感性的影响。我们证明,在体内原发性淋巴瘤中评估时,Bcl-2癌蛋白会产生多药耐药性。相比之下,当原发性淋巴瘤进行长期培养时,这种效应会显著降低,而在标准的克隆形成存活试验中则完全未出现。该模型突出了生理测试系统对于解决临床耐药复杂性的重要性,并提供了一种评估针对特定基因损伤的化合物的新策略。